...
首页> 外文期刊>Journal of pediatric gastroenterology and nutrition >Liver histology of children with chronic hepatitis treated with interferon-alpha alone or in combination with lamivudine.
【24h】

Liver histology of children with chronic hepatitis treated with interferon-alpha alone or in combination with lamivudine.

机译:单独或与拉米夫定联合使用干扰素-α治疗的慢性肝炎儿童的肝组织学。

获取原文
获取原文并翻译 | 示例

摘要

AIM: To evaluate histological changes with interferon monotherapy or interferon plus lamivudine combination therapy in children with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B. PATIENTS AND METHODS: 31 children aged 2-13 years were randomly treated with interferon (IFN) (group 1, n = 16) or IFN plus simultaneously started lamivudine (group 2, n = 15). IFN-alpha 2a was given 9 MU/m2 3 times per week for 6 months in each group; lamivudine was given 4 mg x kg(-1) x day(-1) for 24 months. Liver biopsy specimens were evaluated according to the Knodell score before therapy and after 24 months of therapy. Histological response was defined as a decrease in the histological activity index (HAI) score by at least 2 points. Efficacy of therapy was evaluated at 24 months of therapy in all children. RESULTS: Alanine aminotransferase normalization, HbeAg, and hepatitis B virus DNA clearance were not different. Complete response and histological response were 37.5%/62.5% and 40%/46.7% in groups 1 and 2, respectively (P = NS). At baseline and at 24 months of therapy, total HAI and components of HAI were not different in the 2 groups. In comparison with baseline, a significant decrease in scores of periportal +/- bridging necrosis was observed in group 1 (P = 0.01); periportal +/- bridging necrosis, intralobular degeneration, focal necrosis, and necroinflammation scores significantly decreased in group 2 (P = 0.04 and P = 0.02) at 24 months of therapy. CONCLUSIONS: The addition of lamivudine to IFN-alpha did not increase the effectiveness of the treatment in terms of complete and histological responses. Both therapies seemed to be effective in the regression of periportal +/- bridging necrosis. In addition, combination therapy was also effective in the regression of intralobular degeneration, focal necrosis, and necroinflammatory activity index.
机译:目的:评估使用干扰素单药或干扰素加拉米夫定联合治疗儿童乙型肝炎e抗原(HBeAg)阳性的慢性乙型肝炎的组织学变化。病人和方法:31名2-13岁的儿童随机接受干扰素(IFN)治疗(第1组,n = 16)或IFN加同时开始拉米夫定(第2组,n = 15)。每组每周6次,每周3次给予IFN-alpha 2a 9 MU / m2,共6个月。给予拉米夫定4 mg x kg(-1)x天(-1),持续24个月。根据治疗前和治疗后24个月的Knodell评分评估肝活检标本。组织学反应定义为组织学活动指数(HAI)评分降低至少2分。所有儿童在治疗24个月时均评估了治疗效果。结果:丙氨酸氨基转移酶正常化,HbeAg和乙型肝炎病毒DNA清除率无差异。第1组和第2组的完全缓解和组织学缓解分别为37.5%/ 62.5%和40%/ 46.7%(P = NS)。在基线和治疗24个月时,两组的总HAI和HAI成分无差异。与基线相比,在第1组中观察到门静脉+/-桥接坏死的得分显着降低(P = 0.01);治疗24个月时,第2组的门静脉+/-桥接坏死,小叶内变性,局灶性坏死和坏死性炎症评分显着降低(P = 0.04和P = 0.02)。结论:在完全和组织学应答方面,将拉米夫定添加到IFN-α中并不能提高治疗的有效性。两种疗法似乎在门静脉+/-桥接坏死的消退中是有效的。另外,联合治疗在小叶内变性,局灶性坏死和坏死性炎症指标的消退中也有效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号